NCCN 2019 Annual Congress: Hematologic Malignancies™

Agenda*

 Friday, September 27, 2019
4:30 – 6:00 pm
Registration, Breakfast, and Exhibits

6:00 – 6:05 pm
Opening Remarks
Ranjana H. Advani, MD, Stanford Cancer Institute

6:05 – 6:50 pm

Debate – Evolving Strategies in First-Line Chronic Lymphocytic Leukemia:
Is There a Role for Chemoimmunotherapy?

Facilitated by: Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Presented by:
Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute
William G. Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center

Panelists:
Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center
Jae Park, MD, Memorial Sloan Kettering Cancer Center

 6:55 – 7:25 pm
Updates in Treatment Strategies for Hodgkin Lymphoma
Ranjana H. Advani, MD, Stanford Cancer Institute


7:30 – 8:30 pm
Patient Case Studies and Panel Discussion: 
Lymphoma


Moderated by: Ranjana H. Advani, MD, Stanford Cancer Institute

Panelists:
Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center
Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute
Mrinal Dutia, MD, Kaiser Permanente
Richard I. Fisher, MD, 
​Fox Chase Cancer Center
William G. Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center
Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Saturday, September 28, 2019
7:00 – 8:00 am
Registration, Breakfast, and Exhibits

8:00 – 8:05 am
Opening Remarks
Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

8:05 – 9:05 am
Patient Case Studies and Panel Discussion: 
Leukemia – Rare and Emerging Subtypes


Moderated by: Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Panelists:
Jarrod Holmes, MD, Annadel Medical Group
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center
Jae Park, MD, Memorial Sloan Kettering Cancer Center
Daniel A. Pollyea, MD, MS,
University of Colorado Cancer Center

9:10 – 9:40 am
Management of Recurrent Acute Lymphoblastic Leukemia with T-Cell Engagement: 
CAR T, BiTEs, and Beyond

Jae Park, MD, Memorial Sloan Kettering Cancer Center

9:45 – 10:15 am
Therapeutic Advances in First-Line Acute Myeloid Leukemia Management
Daniel A. Pollyea, MD, MS, University of Colorado Cancer Center

10:15 – 10:40 am
Break and Exhibits

10:40 – 11:10 am
Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes
Rafael Bejar, MD, PhD, UC San Diego Moores Cancer Center

11:15 am – 12:00 pm
Debate – Fixed Duration Versus Until Progression: 
How Long Should the Initial Treatment of Myeloma Last?


Facilitated by: Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Presented by:
Yvonne A. Efebera, MD, MPH, The Ohio State University Comprehensive Cancer Center -
James Cancer Hospital and Solove Research Institute

Noopur Raje, MD, Massachusetts General Hospital Cancer Center

Panelists:
Muhamed Baljevic, MD, Fred & Pamela Buffett Cancer Center
Michaela Liedtke, MD, Stanford Cancer Institute
Thomas G. Martin III, MD, UCSF Helen Diller Family Comprehensive Cancer Center

12:00 – 1:15 pm Lunch and Exhibits

1:15 – 2:15 pm
Patient Case Studies and Panel Discussion: 
Plasma Cell Neoplasms


Moderated by: Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Panelists:
Muhamed Baljevic, MD, Fred & Pamela Buffett Cancer Center
Yvonne A. Efebera, MD, MPH, 
The Ohio State University Comprehensive Cancer Center - 
James Cancer Hospital and Solove Research Institute
 
Michael M. Green, MD, Kaiser Permanente
Michaela Liedtke, MD, Stanford Cancer Institute
Thomas G. Martin III, MD, UCSF Helen Diller Family Comprehensive Cancer Center

2:20 – 2:50 pm
Evolution of Therapy for Relapsed/Refractory Multiple Myeloma
Jorge J. Castillo, MD
Dana-Farber Cancer Institute

2:50 – 3:10 pm
Break and Exhibits

3:10 – 3:40 pm
The Era of Therapeutic Biosimilars Has Arrived: 
What You Need to Know

Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

3:45 – 4:15 pm
Diagnosis and Management of Castleman’s Disease
Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center

4:20 – 4:50 pm
Optimizing First-Line Therapy for Follicular Lymphoma: 
Is It Time for Chemo-Free Therapy? 

Richard I. Fisher, MD, Fox Chase Cancer Center

4:50 - 5:00 pm
Closing Remarks
Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center


 *Agenda is subject to change. Faculty will be updated as confirmed.


Call for Cases: NCCN invites you to submit patient case studies for the NCCN 2019 Annual Congress: Hematologic Malignancies™. Selected case studies will be reviewed at the Congress during interactive panel discussions featuring leading experts and community practitioners. Click here for more information and submit your case at education.nccn.org/NCCNhem19cases. Questions? Contact education@nccn.org.

Top